Funding for this research was provided by:
This research was funded by Angelini Pharma S.p.a.
Received: 29 September 2022
Accepted: 15 November 2022
First Online: 16 December 2022
: Ethics approval of the study was obtained by competent Ethics Committees and Informed consent to participate in the study was obtained from all subjects.
: Not applicable.
: NF and MM are employees of Angelini Pharma. AC has an interest in relation to one or more organizations that could be perceived as a possible competing interest: Advisory board or similar committee: Angelini, Apsen, GlaxoSmithKline, Recordati, Pfizer, Sanofi-Aventis; Clinical trials or studies: Angelini; Boehringer Ingelheim; GlaxoSmithKline; Janssen; Lundbeck; Viatris; Otsuka; Honoraria or other fees: Angelini; Janssen; Lundbeck; Otsuka, Recordati; Sanofi-Aventis; Viatris, Vifor. AB declares relationships with Janssen- Cilag, Lundbeck and Angelini as sponsors of congresses.AF is/has been a consultant and/or a speaker and/or has received research grants from Angelini, Apsen, Boheringer Ingelheim, Daiichi Sankyo, Doc Generici, Glaxo Smith Kline, Italfarmaco, Lundbeck, Janssen, Mylan, Neuraxpharm, Otsuka, Pfizer, Recordati, Sanofi Aventis, Sunovion, Viatris, Vifor. The other authors declare no competing interest.